SCHEMBL26705170

SCHEMBL26705170

CCCC1CCN(CC2CCN(C)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.43
ACHE P22303 3/20 0.42
GNAO1 P09471 3/20 0.42
GNAI3 P08754 2/20 0.42
GNAI1 P63096 2/20 0.42
HRH3 Q9Y5N1 2/20 0.40
CHRM5 P08912 2/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD2 P14416 1/20 0.39
CHRM3 P20309 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
ADRA2C P18825 1/20 0.39
CACNA2D1 P54289 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNB1 Q02641 1/20 0.38
CACNA1C Q13936 1/20 0.38
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17033949 0.90 ACHE (0.47) ACHEGNAO1HRH3CHRM5ADRA2C
SCHEMBL123480 0.87 NCF1 (0.54) NCF1ACHEGNAO1GNAI3GNAI1
SCHEMBL27249928 0.87 GNAO1 (0.50) NCF1ACHEGNAO1GNAI3GNAI1
SCHEMBL26705199 0.86 NCF1 (0.42) NCF1ACHEGNAO1GNAI3GNAI1
SCHEMBL24757176 0.86 ACHE (0.44) ACHEGNAO1HRH3CHRM5ADRA2C
Fluoride SCHEMBL30330327 0.85 NCF1 (0.52) NCF1ACHEGNAO1GNAI3GNAI1
SCHEMBL7738920 0.84 ACHE (0.62) ACHECHRM5ADRA2C
SCHEMBL24319182 0.83 NCF1 (0.46) NCF1ACHEGNAO1GNAI3GNAI1
SCHEMBL24319476 0.83 NCF1 (0.50) NCF1ACHEGNAO1GNAI3GNAI1
SCHEMBL23173902 0.83 NCF1 (0.54) NCF1ACHEGNAO1GNAI3GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 US disclosed
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, SHBG NCF1 3023/4885ACHE 3611/4885GNAO1 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.